Human Umbilical Vein Endothelial Cells < Humans < Hungary

Facettes : Author.f AffPays.f Mesh.f AffRegion.f AffVille.f AffOrg.f

List of bibliographic references

Number of relevant bibliographic references: 2348.
[0-20] [0 - 20][0 - 50][20-40]

Ident.	Authors (with country if any)	Title
000002 (2020)	Charlotte Girard-Guyonvarc'H ; Michele Iudici	[Targeted therapies for connective tissue diseases and vasculitis].
000006 (2020)	Danièle Allali ; Marc Blondon ; Pascale Roux-Lombard ; David Spoerl	[How to manage giant cell arteritis].
000008 (2020)	C B Wu [République populaire de Chine] ; H Y Zhang [République populaire de Chine] ; S H Shao [République populaire de Chine] ; L W Dou [République populaire de Chine] ; Q Y Zhou [République populaire de Chine] ; Y. Liu [République populaire de Chine] ; W B Gao [République populaire de Chine] ; J H Zhu [République populaire de Chine]	[A report of six TAFRO syndrome: clinical characteristics, diagnosis and treatment analysis].
000009 (2020)	Binqing Fu [République populaire de Chine] ; Xiaoling Xu [République populaire de Chine] ; Haiming Wei [République populaire de Chine]	Why tocilizumab could be an effective treatment for severe COVID-19?
000010 (2020)	Seoyoung C. Kim [États-Unis] ; Sebastian Schneeweiss [États-Unis]	When Randomized Clinical Trials and Real-World Evidence Say the Same: Tocilizumab and Its Cardiovascular Safety.
000054 (2020)	Anca D. Askanase [États-Unis] ; Leila Khalili [États-Unis] ; Jill P. Buyon [États-Unis]	Thoughts on COVID-19 and autoimmune diseases.
000076 (2020)		Some drugs for COVID-19.
000077 (2020)	Emre Bilgin [Oman] ; Rem Ozarli [Turquie] ; Levent K L Ç [Turquie] ; Ertu Rul Ça R Bölek [Turquie] ; Gözde Kübra Yard Mc [Turquie] ; Ömer Karada [Turquie]	Some concerns from Turkey.
000093 (2020)	Yuko Kaneko [Japon] ; Hideto Kameda [Japon] ; Kei Ikeda [Japon] ; Tomonori Ishii [Japon] ; Kosaku Murakami [Japon] ; Hyota Takamatsu [Japon] ; Yoshiya Tanaka [Japon] ; Takayuki Abe [Japon] ; Tsutomu Takeuchi [Japon]	Response to: 'Some concerns from Turkey' by Bilgin et al.
000096 (2020)	Angela Ceribelli [Italie] ; Francesca Motta [Italie] ; Maria De Santis [Italie] ; Aftab A. Ansari [États-Unis] ; William M. Ridgway [États-Unis] ; M Eric Gershwin [États-Unis] ; Carlo Selmi [Italie]	Recommendations for coronavirus infection in rheumatic diseases treated with biologic therapy.
000111 (2020)	Ana Luisa Oliveira [Portugal] ; Carina Ruano [Portugal] ; Nuno Riso [Portugal] ; José Cepeda Ribeiro [Portugal] ; Maria Francisca Moraes-Fontes [Portugal]	Paradoxical pulmonary event under tocilizumab treatment for systemic sclerosis-associated usual interstitial pneumonia.
000115 (2020)	Peter N. Taylor [Royaume-Uni] ; Lei Zhang [Royaume-Uni] ; Richard W J. Lee [Royaume-Uni] ; Ilaria Muller [Royaume-Uni] ; Daniel G. Ezra [Royaume-Uni] ; Colin M. Dayan [Royaume-Uni] ; George J. Kahaly [Allemagne] ; Marian Ludgate [Royaume-Uni]	New insights into the pathogenesis and nonsurgical management of Graves orbitopathy.
000131 (2020)	Amit Rout [États-Unis] ; Ajaypaul Sukhi [États-Unis] ; Rahul Chaudhary [États-Unis] ; Kevin P. Bliden [États-Unis] ; Udaya S. Tantry [États-Unis] ; Paul A. Gurbel [États-Unis]	Investigational drugs in phase II clinical trials for acute coronary syndromes.
000134 (2020)	Peter Uciechowski [Allemagne] ; Wolfram C M. Dempke [Allemagne]	Interleukin-6: A Masterplayer in the Cytokine Network.
000145 (2020)	Anna-Sophia Kattner [Allemagne] ; Ernst Holler [Allemagne] ; Barbara Holler [Allemagne] ; Sebastian Klobuch [Allemagne] ; Daniela Weber [Allemagne] ; Danilo Martinovic [Allemagne] ; Matthias Edinger [Allemagne] ; Wolfgang Herr [Allemagne] ; Daniel Wolff [Allemagne]	IL6-receptor antibody tocilizumab as salvage therapy in severe chronic graft-versus-host disease after allogeneic hematopoietic stem cell transplantation: a retrospective analysis.
000146 (2020)	Etienne Dufranc [France] ; Arnaud Del Bello [France] ; Julie Belliere [France] ; Nassim Kamar [France] ; Stanislas Faguer [France]	IL6-R blocking with tocilizumab in critically ill patients with hemophagocytic syndrome.
000148 (2020)	Heidi Ledford	How does COVID-19 kill? Uncertainty is hampering doctors' ability to choose treatments.
000153 (2020)	Xuhan Zhang [République populaire de Chine] ; Kaidi Song [République populaire de Chine] ; Fei Tong [République populaire de Chine] ; Mingming Fei [République populaire de Chine] ; Hui Guo ; Zhaohui Lu [République populaire de Chine] ; Jinquan Wang [République populaire de Chine] ; Changcheng Zheng [République populaire de Chine]	First case of COVID-19 in a patient with multiple myeloma successfully treated with tocilizumab.
000170 (2020)	Tomoyuki Asano ; Shuzo Sato ; Jumpei Temmoku ; Yuya Fujita ; Makiko Yashiro Furuya ; Naoki Matsuoka ; Hiroko Kobayashi ; Eiji Suzuki [Japon] ; Hiroshi Watanabe ; Kiyoshi Migita	Effectiveness of Tocilizumab in juvenile patients with refractory Takayasu arteritis: Two case reports.
000186 (2020)	Catalina Sanchez-Alvarez [États-Unis] ; Matthew Koster [États-Unis] ; Ali Duarte-García [États-Unis] ; Kenneth J. Warrington [États-Unis]	Disease progression of Takayasu arteritis in two patients treated with tocilizumab.
000194 (2020)	Melissa Bersanelli [Italie]	Controversies about COVID-19 and anticancer treatment with immune checkpoint inhibitors.

---

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Sante/explor/TocilizumabV1/Data/PubMed/Checkpoint

HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/MedMesh.i -k "Humans" 

HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/MedMesh.i  \
                -Sk "Humans" \
         | HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd 

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Sante
   |area=    TocilizumabV1
   |flux=    PubMed
   |étape=   Checkpoint
   |type=    indexItem
   |index=    MedMesh.i
   |clé=    Humans
}}

---

This area was generated with Dilib version V0.6.34. Data generation: Fri May 22 09:34:00 2020. Site generation: Sun Mar 28 09:01:19 2021